Project Grant F30CA310107
Award Date 12/1/26
Completion Date 4/16/30
Dollars Obligated $108K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary Baylor College of Medicine received a $160,500 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for June 30, 2027. The award funds the development and investigation of in vivo murine models to examine the role of caspase-2 in nucleophosmin-mutated acute myeloid leukemia (NPM1C+ AML). The research deliverables include the establishment of transgenic mouse...
- Federal Grant Award Summary Baylor College of Medicine received a $2.4 million Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective August 15, 2025 through July 31, 2029. The award funds research investigating the role of RNA sequestration in acute myeloid leukemia (AML), specifically examining how the RNA helicase DDX6 (DEAD-Box Helicase 6) regulates post-transcriptional processes critical to leukemia development and...
- Federal Project Grant Award Summary Baylor College of Medicine received a $191,681 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2026 through June 30, 2029. The award supports biomedical research training and workforce development focused on cancer research aligned with the National Cancer Program. As a research-intensive academic health sciences institution, Baylor will provide structured training opportunities...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center $112,806 through the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, to support biomedical training and workforce development in cancer research. The award, which extends through April 30, 2028, funds a research training initiative investigating the role of CARM1-mediated methylation of QKI (quaking) protein in glioblastoma stem cell maintenance and tumor development. The project...
- Federal Project Grant Award Summary Award Details: Baylor College of Medicine received a $197,600 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 20, 2027. Products and Services: This award funds the development and validation of RECON (Reconstitution of Endogenous Control), a novel immune tolerization strategy designed to advance cancer research by enabling researchers to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded The University of Texas Southwestern Medical Center a $688,012 Project Grant effective June 1, 2026, through May 31, 2031. This award supports the development of novel RPS23 (ribosomal protein S23) inhibitors for the treatment of acute myeloid leukemia (AML). The research will advance a therapeutic strategy targeting the integrated stress response (ISR)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded The Jackson Laboratory $136,687 on July 15, 2026, to support research training and scientific investigation into the roles of ZBTB7 paralogs in leukemogenesis. This award supports a dual-phase training and research initiative aimed at understanding how tumor suppressor genes are inactivated at the post-transcriptional level in acute myeloid leukemia (AML) and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Baylor College of Medicine a $882,470 Research Specialist (Clinician Scientist) Award under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2030. The award supports clinical leadership and trial development services focused on pediatric and adolescent cancer patients with hematologic malignancies. The primary deliverables include establishment and facilitation of a...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $434,969 to the University of Pennsylvania on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate cellular mechanisms underlying acute myeloid leukemia (AML) persistence during FLT3 (Fms-like tyrosine kinase 3) inhibitor therapy. The five-year project, completing April 30, 2031, combines genetically engineered mouse models with human specimen analysis to determine which leukemic cell...